ArticleBMC infectious diseases2023
Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015-2018.
Article in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 62 citations in OpenAlex.
- Cost-Effectiveness of Maternal RSVpreF Vaccination Compared with Newborn Nirsevimab RSV Prophylaxis or No RSV Prophylaxis in Switzerland.Applied health economics and health policy · 2026Article
- Article
- The Impact of Nirsevimab on the Transport of Critically Ill Children.Children (Basel, Switzerland) · 2026Article
- Adult RSV hospitalizations in Spain: clinical characteristics and risk factors for ICU admission, prolonged stay, and mortality across six seasons (2016-2017 to 2021-2022).Frontiers in public health · 2026Article
- Epidemiology and economic burden of hospitalizations attributable to Respiratory Syncytial Virus (RSV) infection among infants in France, 2016 to 2023 - EPIBREATHE study.BMC infectious diseases · 2025Article
- Impact of RSV hospitalization on healthcare costs, caregivers' productivity loss, and quality of life in children ≤ 2 years old in five European countries.European journal of pediatrics · 2025Article
- Impact of universal nirsevimab prophylaxis on clinical and ultrasound presentations of lower respiratory tract infections in hospitalized pediatric patients.European journal of pediatrics · 2025Observational
- Dynamics of RSV hospitalization rates in ≤ 2-year-old children between 2020-2023 in Europe.European journal of pediatrics · 2025Article
- Predicting regional and temporal incidence of RSV and influenza hospitalizations in a birth cohort of young Australian children.Scientific reports · 2025Article
- Respiratory Syncytial Virus (RSV) as a Secondary Diagnosis among Hospitalized Patients in Germany: Outcomes and Economic Burden.Infectious diseases and therapy · 2025Article
- Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants.Influenza and other respiratory viruses · 2025Article
- DNA methylation signatures of severe RSV infection in infants: evidence from non-invasive saliva samples.Epigenetics & chromatin · 2025Article
- Hospitalizations for bronchiolitis among infants before and after the SARS-CoV-2 pandemic: an area-based study of the Emilia-Romagna Region, Italy.Italian journal of pediatrics · 2025Article
- Burden and Economic Impact of Respiratory Viral Infections in Adults Aged 60 and Older: A Focus on RSV.Diseases (Basel, Switzerland) · 2025Article
- Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study.BMJ public health · 2025Article
- Impact of Respiratory Syncytial Virus (RSV) in Adults 60 Years and Older in Spain.Geriatrics (Basel, Switzerland) · 2024Article
- Respiratory Syncytial Virus Risk Profile in Hospitalized Infants and Comparison with Influenza and COVID-19 Controls in Valladolid, Spain, 2010-2022.Infectious diseases and therapy · 2024Article
- Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain.Vaccines · 2024Article
- Impact of twelve immunization-preventable infectious diseases on population health using disability-adjusted life years (DALYs) in Spain.BMC infectious diseases · 2024Article
- Cost-effectiveness Analysis of Maternal Immunization with RSVpreF Vaccine for the Prevention of Respiratory Syncytial Virus Among Infants in Spain.Infectious diseases and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infection (ALRI) in children, causing frequent outpatient visits and hospitalizations. Our study aimed to describe the clinical and direct economic burden of ALRI hospitalizations related to RSV in children in Spain and the characteristics of patients and their episodes. In this retrospective study, ALRI hospitalizations in children aged < 5 years for 2015-2018 were reviewed using anonymized administrative public hospital discharge data from Spain. Three case definitions were considered: (a) RSV-specific; (b) RSV-specific and unspecified acute bronchiolitis (RSV-specific and bronchiolitis); and (c) RSV-specific and unspecified ALRI (RSV-specific and ALRI). The study reported a mean of 36,743 yearly admissions potentially due to RSV, resulting in a mean annual cost of €87.1 million. RSV-specific codes accounted for 39.2% of cases, unspecified acute bronchiolitis for 20.1%, and other unspecified ALRI codes for the remaining 40.6%. The mean hospitalization rate per 1,000 children was 55.5 in the first year of life, 16.0 in the second, and 5.4 between 24 and 59 months. A considerable proportion of cases occurred in children under two years old (> 80.4%) and even during the first year of life (> 61.7%). Otherwise healthy children accounted for 92.9% of hospitalizations and 83.3% of costs during the period. Children born preterm accounted for 1.3% of hospitalizations and 5.7% of costs. The findings revealed that RSV still contributes to a high burden on the Spanish health care system. Children under one year of age and otherwise healthy term infants accounted for most of the substantial clinical and economic burden of RSV. Current evidence potentially underestimates the true epidemiology and burden of severe RSV infection; thus, further studies focusing on the outpatient setting are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.